{"id":"NCT02026063","sponsor":"Lexicon Pharmaceuticals","briefTitle":"Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms","officialTitle":"A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01-14","primaryCompletion":"2018-09-12","completion":"2018-09-12","firstPosted":"2014-01-01","resultsPosted":"2019-09-17","lastUpdate":"2019-09-17"},"enrollment":124,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoid Syndrome"],"interventions":[{"type":"DRUG","name":"Telotristat etiprate","otherNames":["LX1606"]}],"arms":[{"label":"250 mg Telotristat Etiprate","type":"EXPERIMENTAL"},{"label":"500 mg Telotristat Etiprate","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"First dose of study drug (Day 1) up to 15 days post last dose (approximately up to 236 weeks)","effectByArm":[{"arm":"Telotristat Etiprate 250 mg","deltaMin":22,"sd":null},{"arm":"Telotristat Etiprate 500 mg","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":43,"countries":["United States","Australia","Belgium","Canada","France","Germany","Israel","Italy","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["33940581"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":22},"commonTop":["Diarrhoea","Nausea","Abdominal pain","Fatigue","Constipation"]}}